Farmak International Expands UK Portfolio with Three New MHRA-Approved Therapies
We are excited to share that Farmak International’s UK & Ireland affiliate has just secured three more MHRA-approved medicines.
These approvals not only broaden our hospital- and retail-focused range but also ensure you have reliable, ready-to-order therapies when and where patients need them.
What’s New in Your Catalogue:
1 – Iohexol Injection – Advanced Diagnostic Imaging
Now available for CT scans, angiography, myelography, body-cavity exams, and contrast-enhanced mammography, Iohexol gives radiology departments a single, trusted medium, so you can cut down on supplier complexity and keep imaging schedules on track.
2 – Ranolazine Elara Prolonged-Release Tablets – Stable Angina Relief
As an add-on for patients whose angina is not fully managed by beta-blockers or calcium antagonists, these tablets help cardiology teams expand their treatment options without juggling multiple dossier submissions.
3 – Paracetamol Capsules – Fast-Acting Analgesic & Antipyretic
From migraine relief to post-operative fever control, adding these capsules to your formulary means pharmacy teams can consolidate low-risk pain and fever management into a single, fully authorised product.
Seamless Supply, Stronger Tenders
By building on our existing UK portfolio, you benefit immediately from:
Consistent Availability: All three products are ready to ship, with no back-order worries
Tender-Ready Documentation: Our proven MHRA dossiers simplify your bid submissions, helping you hit every deadline with confidence.
One Partner, Broader Coverage: Fewer vendors to manage across ICU, cardiology, and imaging, streamlining your procurement and logistics.
Looking Ahead:
In line with our commitment to support the NHS and drive operational resilience, we have submitted two more hospital-focused therapies through MHRA’s fast-track reliance pathway so Farmak International can bring essential treatments on board quickly in our next tender rounds and bolster patient care capacity.
Building a hospital- and retail-focused portfolio in the UK has been our top priority, and these approvals show just how fast we are scaling. Our goal is to make it as easy as possible for distributors and hospital teams to access critical-care, diagnostic, and retail medicines exactly when they are needed. Marc Hourigan Head of UK & Republic of Ireland
Next Steps:
Ready to add these therapies to your offering? Email our UK team: info@farmak.uk
Explore the full line-up: Products UK – FARMAK International
